Sarcopenia and Its Prognostic Role on Hospitalization and In-Hospital Mortality in Coronavirus Disease 2019 Patients with At Least One Cardiovascular Risk Factor

Kardiyovasküler En Az Bir Risk Faktörü Olan COVID-19 Hastalarında Sarkopeninin Hastaneye Yatış ve Hastane İçi Mortalite Üzerindeki Prognostik Rolü

ABSTRACT

Background: The coronavirus disease 2019 infection is a global pandemic that has affected the whole world population. We aimed to evaluate the prognostic role of cross-sectional area, muscle index, and muscle attenuation values in computed tomography–based skeletal groups [erector spinae muscle, pectoralis muscle, and total skeletal muscle] of patients hospitalized for coronavirus disease 2019 and with at least 1 cardiovascular risk factor.

Methods: A total of 232 patients with coronavirus disease 2019 and at least 1 cardiovascular risk factor were enrolled in the study, retrospectively. The cross-sectional area, muscle index, and attenuation of erector spine muscle, pectoralis muscle, and total skeletal muscle were automatically measured on computed tomography images. The study population was assigned into tertiles on the basis of the total SMcsa index. The relationship between the values obtained and the length of hospital stay, admission to intensive care unit, the need for invasive mechanical ventilation, and mortality was investigated.

Results: Admission to intensive care unit, need for invasive mechanical ventilation, and mortality were higher at tertile 3 groups than in the other groups (all \(P < .001\)). Statistically, all muscle measurements were significantly lower in tertile 3 (\(P < .001\)). Diabetes mellitus, hypertension, and total SMcsa index were predictors of in-hospital mortality in patients with coronavirus disease 2019 on the basis of Cox regression analysis. In the Kaplan–Meier analysis for the proportion of survivors relative to the total SMcsa index, tertile 3 had the highest mortality (survival rates 57%, \(P < .001\)).

Conclusions: Sarcopenia and attendant cardiovascular comorbidities can effectively assess disease severity and predict outcome in patients with coronavirus disease 2019.

Keywords: COVID-19, cardiovascular disease, sarcopenia, mortality, prognosis

ÖZET

Amaç: Koronavirüs hastalığı 2019 (COVID-19) enfeksiyonu, tüm dünyada etkili olan küresel bir salgındır. COVID-19 nedeniyle hastaneye yatılan ve en az bir kardiyovasküler risk faktörü olan hastaların bilgisayarlı tomografi (BT) ile iskelet kas gruplarında [erektör spina (ESK), pektoral (PK) ve toplam iskelet kasında (Toplam İK)] kesitsel alanı (kda), kas indeksi ve kas atenüasyonunun (ka) prognostik rolünü değerlendirmeyi amaçladık.

Yöntemler: Çalışmaya COVID-19 ve en az bir kardiyovasküler risk faktörü olan hastalar 232 hasta geri döndük olarak dahil edildi. ESK, PK ve Toplam İK indeksin kda, indeksi ve atenüasyonu BT görünür tüllerinde otomatik olarak ölçülüyor. Çalışma popülasyonu, Toplam İK kde indeksinin değerlendirildiği tertilere bölündü. Elde edilen değerler ile hastanede kalış süresi, yoğun bakım ünitesine (YBU) yatış, invaziv mekanik ventilasyon (IMV) ihtiyacını ve mortalite açısından ilgi alanı araştırıldı.

Bulgular: YBU'ya başvuru, IMV ihtiyacını ve mortalite tertil 3’de diğer gruplara göre daha yüksekti (tüm \(P < .001\)). Yüksek mortalite tertil 3’te istatistiksel olarak anlaşılmadı derecede düştüktü (\(P < .001\)). Diabetes mellitus, hipertansiyon ve Toplam İK indeksinde çok değişiklikli Cox analizine göre COVID-19 hastalarında hastane içi mortalitenin öngörüldüğü drandır. Hayatta kalanların oranı için Kaplan–Meier eğrileri, tertil 3’teki Toplam İKter indeksine yüksek mortaliteye sahiptir (hayatta kalan oran %57, \(P < .001\)).

Sonuçlar: Sarcopeni ve estıjen eden kardiyovasküler komorbiditeler, COVID-19 hastalarında hastalık şiddetini etkili bir şekilde değerlendirilebilir ve sonucu tahmin edebilir.

Anahtar Kelimeler: COVID-19, kalp-damar hastalığı, sarcopeni, ölüm, прогноз

ORIGINAL ARTICLE

KLİNiK ÇALIŞMA

Mehmet Akif Erdöl, M.D. 1,2
Bircan Kayaaslan, M.D. 3,4
Mehmet Erdoğan, M.D. 1,2
İmran Hasanoğlu, M.D. 1
Çağın Yayla, M.D. 5
Fatma Civelek Eser, M.D. 2
Muhammed Said Beşler, M.D. 6
Ayşe Kaya Kalem, M.D. 7
Kadriye Gayretli Yayla, M.D. 8
Ayşe Kevser Erdöl, M.D. 9
Atıfah Rahmet Güner, M.D. 2

1Cardiology Unit, University of Health Sciences, Ankara City Hospital, Turkey
2Department of Infectious Diseases and Clinical Microbiology, Ankara Yıldırım Beyazıt University, Faculty of Medicine, Turkey
3Radiology Unit, University of Health Sciences, Ankara City Hospital, Turkey
4Cardiology Unit, University of Health Sciences, Dr. Abdurrahman Yurtaslan Ankara Oncology, Training and Research Hospital, Turkey
5Pulmonary Medicine Unit, University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Turkey

Corresponding author: Mehmet Akif Erdöl

DOI:10.5543/tkda.2022.21167

Accepted: October 20, 2021

Cite this article as: Erdöl MA, Kayaaslan B, Erdoğan M, et al. Sarcopenia and its prognostic role on hospitalization and in-hospital mortality in coronavirus disease 2019 patients with at least one cardiovascular risk factor. Turk Kardiyol Dern Ars 2022;50(2):103–111. Available online at archivescsc.com. Content of this journal is licensed under a Creative Commons Attribution – NonCommercial-NoDerivatives 4.0 International License.
In Wuhan, Hubei province, China, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first identified in December 2019, after which the virus was defined coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). In Turkey, from January 3, 2020, to June 28, 2021, there were 5449464 confirmed COVID-19 cases and 49959 patients died. While real-time reverse transcription polymerase chain reaction (RT–PCR) is the important test for diagnosis, chest computed tomography (CT) is a cornerstone in the evaluation of patients diagnosed and treatment management.

Sarcopenia is a generalized, progressive disease with a decrease in muscle quality and quantity. Comorbidities such as coronary artery disease (CAD), diabetes mellitus (DM), and chronic obstructive pulmonary disease (COPD) are common with sarcopenia, and mortality is higher in these patients. Many studies have shown that relationship between mortality and erector spinae muscle (ESM), pectoralis muscle (PM), and total skeletal muscle (total SM) cross-sectional area and index (divided by height squared) obtained from thorax CT. The relationship between mortality and erector spinae muscle (ESM), pectoralis muscle (PM), and total skeletal muscle (total SM) cross-sectional area and index (divided by height squared) obtained from thorax CT. Many studies have shown that relationship between mortality and erector spinae muscle (ESM), pectoralis muscle (PM), and total skeletal muscle (total SM) cross-sectional area and index (divided by height squared) obtained from thorax CT.

The median follow-up duration of the participants was 11 (8–15) days. Minimum and maximum follow-up durations were 1 and 48 months, respectively. The primary end-point of the study was in-hospital all-cause mortality.

Data Collection and Analysis
Information on demographic characteristics (gender and age), presence of COPD, hypertension (HTN), DM, CAD, cerebrovascular disease, peripheral vascular disease, dyslipidemia, renal and liver failure, smoking, clinical manifestations, laboratory findings, treatment and outcomes (duration of hospitalization/ICU/IMV/death) were extracted from electronic medical records using a standardized data collection form. Coronary artery disease was defined as a history of myocardial infarction or primary percutaneous intervention or a stenosis of more than 50% in any coronary vessel. Hypertension was defined as receiving antihypertensive treatment and/or arterial blood pressure > 140/90 in more than 1 measurement. Diabetes mellitus diagnosis, history of DM and/or antidiabetic therapy, or postprandial blood glucose level > 200 mg/dL were accepted as DM. Total cholesterol > 200 mg/dL, low-density lipoprotein > 130 mg/dL, history of dyslipidemia, and/or being under antilipidemic treatment were accepted as hyperlipidemia. Data on medical treatments of the patients (renin–angiotensin–aldosterone system (RAAS) blockers, beta blockers, diuretics, calcium channel blockers, statins, antplatelets, anticoagulations, and oral antidiabetics) were noted.

Routine blood examinations were complete blood count (CBC), coagulation profile, serum biochemical tests (including renal and liver function, creatine kinase, lactate dehydrogenase, and electrolytes), myocardial enzymes, C-reactive protein (CRP), procalcitonin (PCT), serum ferritin, interleukin–6 (IL–6), d-dimer, and arterial blood gases (lactate and PaO2/FiO2 ratio) were collected at admission. Peripheral venous blood samples were obtained from a large antecubital vein at admission. Total CBC test (Sysmex K–1000, Kobe, Japan) and blood chemistry parameters (Roche Diagnostic Modular Systems, Tokyo, Japan) were carried out at the biochemistry laboratory of our hospital. Blood samples were taken in standardized EDTA-containing tubes for total CBC test, and measurements were performed immediately after the blood sampling. Serum CRP levels were measured by immune nephelometric method (NFL BN-II; Dade Behring, Siemens). PCT was determined by bioMérieux MINI Vidas automatic fluorescence immunoanalyzer. Serum ferritin levels were detected by electrochemiluminescence method (Cobas E601, Roche). Interleukin–6 was measured by Roche Cobas
E601 electrochemical luminescence immune detector, using the corresponding reagent. D-dimer was quantitatively determined using Sysmex CS-5100 hemagglutinin analyzer. Chest radiographs and CT scan were also performed for all inpatients.

Throat swab samples were obtained from all suspected patients, and laboratory validation of COVID-19 was performed using RT-PCR in accordance with the manufacturers’ protocol (Dade Behring, Siemens, Deerfield, Illinois, USA; Beijing Genomics Institute, Beijing, China; Shanghai Geneodx Biotechnology Co. Ltd, Shangai, China). Repeated testing for COVID-19 was performed on confirmed patients to verify viral clearance before hospital discharge.

Computed Tomographic Image Analysis and Acquisition

For patients who applied to the hospital with suspicion of COVID-19, multidetector CT (MDCT) examination was performed at the time of admission. All imaging was performed using a 128-slice (Revolution EVO, General Electric (GE) Boston, Massachusetts, USA) MDCT scanner. The CT images were reconstructed using the mediastinal setting for quantitative analysis (Advantage Workstation 4.7 (Revolution, GE Healthcare, USA). We analyzed single-slice axial CT images taken at the lower margin of the 12th thoracic vertebra to measure the cross-sectional area and muscle attenuation of the erector spinae muscle (ESM). The quantitative analysis of the pectoralis muscle (PM) (pectoralis major and minor muscles) was applied on an axial slice just above the aortic arch. Bilateral muscles are colored green (ESM and PM).

Statistical Analysis

Statistical analyses were carried out using IBM Statistical Package for the Social Sciences Statistics for Macintosh, Version 24.0 (IBM Corp., Armonk, NY, USA). One-sample Kolmogorov–Smirnov test was used to evaluate the distribution of numerical variables. One-way analysis of variance test was applied to the numerical data which conform to the normal distribution, and
the results were entered as mean and standard deviation. On the other hand, Kruskal–Wallis test which is one of the non-parametric tests was used for the non-normal distribution variables. Considering the results of this test, the median and interquartile range values were used. Chi-square test was used for categorical variables. Fisher’s exact test was applied in cases where chi-square test could not be applied. For correlation analyses regarding CT-based skeletal measurements (PMcsa index, PMma, ESMcsa index, ESMma, and total SMcsa index), Pearson’s correlation analysis was preferred for data with normal distribution, and Spearman’s correlation analysis was preferred for data with non-normal distribution. The study population was assigned into tertiles on the basis of total SMcsa index.

Cumulative survival rates were calculated by the Kaplan–Meier method and compared between the 2 groups using the log-rank test. Cox proportional hazard regression analysis was performed through enter method to identify predictors for in-hospital mortality. Total SMcsa index was investigated in multivariate models. The models were adjusted for clinical and laboratory features (age, gender, DM, HTN, CAD, and high-sensitive troponin I (hs-TnI) levels). The multicollinearity assessment was checked with correlation coefficient (r) value. Independent variables with correlation coefficient (r) above 0.7 were considered to have multicollinearity and were not included in the same multivariate model. The results of Cox regression analysis were reported with hazard ratio (HR) and 95% CI. Receiver operating characteristic (ROC) curve analyses were used to determine the cut-off values for the sensitivity and specificity of CT–based SM measurements for predicting survival. The area under the ROC curve (AUC) was reported with 95% CI in addition to sensitivity and specificity. A two-tailed test was used and P values lower than .05 were considered to be statistically significant.

Results

The demographic, clinical, and in–hospital status of the study subjects are shown in Table 1. The median age of tertiles 1, 2, and 3 was 43 (34-55), 51 (36-63), and 73 (47-80) years, respectively (P < .001). Male gender was the highest in tertile 1 group than in the other groups (P < .001). Diabetes mellitus, HTN, COPD, CAD, and dyslipidemia were the highest in tertile 3 group (all P values < .05). The usage of RAAS blockers, beta blockers, statins, oral antidiabetics, antiplatelet, and anticoagulant agents

| Variables | All (n = 232) | Tertile 1 (highest) (n = 78) | Tertile 2 (middle) (n = 77) | Tertile 3 (lowest) (n = 77) | P |
|-----------|--------------|-----------------------------|-----------------------------|-----------------------------|---|
| Age (years) | 51 (37-71) | 43 (34-55) | 51 (36-63) | 73 (47-80) | <.001 |
| Sex (male) | 117 (50%) | 57 (73%) | 28 (36%) | 32 (42%) | <.001 |
| Diabetes mellitus | 84 (36%) | 21 (27%) | 28 (37%) | 35 (46%) | .021 |
| Hypertension | 101 (43%) | 21 (27%) | 28 (36%) | 52 (67%) | <.001 |
| Dyslipidemia | 47 (20%) | 11 (14%) | 10 (21%) | 26 (33%) | .001 |
| Coronary artery disease | 42 (18%) | 6 (8%) | 13 (12%) | 23 (30%) | <.001 |
| COPD | 20 (9%) | 2 (3%) | 3 (4%) | 15 (20%) | <.001 |
| Medication | | | | |
| RAAS blockers | 67 (29%) | 10 (13%) | 17 (22%) | 40 (52%) | <.001 |
| Beta blockers | 34 (15%) | 4 (5%) | 8 (10%) | 22 (29%) | <.001 |
| Diuretics | 48 (21%) | 9 (11%) | 11 (23%) | 28 (36%) | <.001 |
| Calcium channel blockers | 31 (13%) | 9 (11%) | 8 (10%) | 14 (18%) | .308 |
| Statins | 28 (12%) | 2 (3%) | 7 (9%) | 19 (25%) | <.001 |
| Antiplatelets | 33 (14%) | 4 (5%) | 9 (12%) | 20 (26%) | .001 |
| Anticoagulations | 8 (3%) | 0 (0%) | 2 (3%) | 6 (8%) | <.001 |
| Oral antidiabetics | 68 (30%) | 15 (19%) | 25 (33%) | 28 (36%) | .016 |
| Outcomes | | | | |
| ICU | 73 (31%) | 11 (14%) | 16 (21%) | 46 (60%) | <.001 |
| Stays in ICU, days | 10 (4.5–18.5) | 6 (3–11) | 12 (8–20.5) | 10.5 (5–20) | .185 |
| Duration of hospitalization, days | 11 (8–15) | 10 (7–13) | 11 (8–15) | 12 (8–19) | .183 |
| IMV | 46 (20%) | 4 (5%) | 9 (12%) | 33 (43%) | <.001 |
| In–hospital mortality | 44 (19%) | 3 (4%) | 8 (10%) | 33 (43%) | <.001 |

COPD, chronic obstructive pulmonary disease; ICU, intensive care unit; IMV, invasive mechanical ventilation; RAAS blockers, renin–angiotensin–aldosterone system. Parameters are mean ± standard deviation or median (interquartile range), n (%). P value less than .05 was considered significant for statistical analyses.
were the highest in tertile 3 group than the other groups (all P values < .05).

Admission to ICU, need of IMV, and in-hospital mortality were common in tertile 3 group than the other groups (all P values < .001) (Figure 2). There were no differences between the 3 groups in terms of stays in ICU and duration of hospitalization (P = .185 and P = .183, respectively).

As shown in Table 2, there were no significant differences in terms of glucose, serum creatinine, and platelet counts between 3 groups on the admission (all P values > .05). The levels of d-dimer, ferritin, CRP, PCT, neutrophil counts, lymphocyte counts, and hemoglobin were the highest in tertile 3 group (all P values < .05). In CT-based SM measurements in Table 2, all muscle measurements (PMcsa, PMcsa index, PMma, EScsa, EScsa index, and EScsai) were statistically significantly lower in tertile 3 (P < .001).

As shown in Table 3, there were significant correlations between total SMcsa index and multiple variables (in terms of age, albumin, d-dimer, PTC, CRP, hs-TnI, neutrophil count, and lymphocyte count; all P values < .05).

Univariate and multivariate Cox proportion regression analyses revealed that (Table 4) DM, HTN, and total SMcsa index were shown to be associated with predicted in-hospital mortality in patients with COVID-19 on the basis of multivariable Cox regression analysis (HR 2.63, 95% CI 1.35–5.11, P = .005; HR 2.98, 95% CI 1.20–7.37, P = .018; HR 0.90, 95% CI 0.85–0.95, P < .001, respectively). The total SMcsa index cut-off value at admission for predicting in-hospital mortality in the entire study population based on ROC analysis was determined as <21.7 cm², with a sensitivity of 75% and a specificity of 80% (AUC 0.85, 95% CI: 0.78–0.91, P < .001) (Table 5) (Figure 3).

Discussion

In our study, we found that age, DM, HTN, and total SMcsa index in patients with COVID-19 is the independent predictor of the mortality. Sarcopenia is a progressive SM disease related with an increased likelihood of worse outcomes, including falls, fractures, physical disability, morbidity, and mortality. Sarcopenia is defined with 3 criteria: (1) low muscle strength, (2) low muscle quantity or quality, and (3) low physical performance. Several studies have observed that the region of the psoas, PM, and paravertebral muscles is related with lean muscle mass, hand-grip strength, health, and sarcopenia on CT scans. There are many advantages of measuring SM to detect sarcopenia. First, the measurement is easy and reliable to perform using open source software (3D Slicer). Previous researches have shown that the slice used to make the measurement is easily identified in CT scans. Progressive reduction in muscle mass and accompanying decrease in muscle strength are related with pathologies including cardiovascular disease, type 2 DM, disability and frailty, increased risk of falls and fractures, decreased physical independence, cognitive
A new type of coronavirus (SARS-CoV-2) was detected, and the WHO named the infection of SARS-CoV-2 as "corona-virus disease 2019 (COVID-19)" in December 2019. The COVID-19 pandemic is an extraordinary global emergency with over 183.9 million confirmed cases and more than 3,800,000 deaths as of July 06, 2021.2

Hospitalization due to COVID-19 can lead to prolonged bed rest. The more severe presentation of COVID-19 infection may result in the need for ICU or IMV. Such long periods of bed rest and hospitalization as a result of COVID-19 isolation/quarantine or hospitalization pose a greater risk of muscle loss, especially for older individuals.18

Du et al19 reported that advanced age and comorbid cerebrovascular or cardiovascular diseases were robust and independent predictors of mortality in patients with COVID-19.19 In addition, Petrilli et al20 reported that advanced age (>75 years of age), male gender, malignancy, and heart failure were independent predictors of mortality in patients with COVID-19.19 In our study, we found similar results to the literature. Hypertension is a significant and powerful risk factor for mortality.17 In our study, we found similar results to the literature. Hypertension is a significant and powerful risk factor for mortality.17

### Table 2. Biochemical and Radiological Parameters of Patients with Total Skeletal Muscle Cross-Sectional Area Index Tertile Comparison

| Variables                          | All (n = 232) | Tertile 1 (Highest) (n = 78) | Tertile 2 (Middle) (n = 77) | Tertile 3 (Lowest) (n = 77) | P     |
|------------------------------------|--------------|-----------------------------|-----------------------------|-----------------------------|-------|
| Glucose (mg/dL)                    | 102 (91-126) | 102 (91-116)                | 97 (91-122)                 | 107 (89-155)                | .405  |
| BUN (mg/dL)                        | 31 (24-41)   | 29 (24-36)                  | 30 (23-39)                  | 38 (24-54)                  | .001  |
| Creatinine (mg/dL)                 | 0.84 (0.67-1.04)| 0.86 (0.70-1.05)| 0.78 (0.65-0.96)| 0.84 (0.64-1.11) | .090  |
| Sodium (mEq/L)                     | 139 (136-141)| 139 (138-141)               | 139 (137-141)               | 138 (134-141)               | .136  |
| Potassium (mEq/L)                  | 4.1 (3.9-4.4)| 4.0 (3.8-4.3)               | 4.1 (3.9-4.4)               | 4.1 (3.9-4.5)               | .325  |
| AST (U/L)                          | 26 (18-42)   | 27 (19-39)                  | 22 (16-32)                  | 31 (18-57)                  | .003  |
| Albumin (g/dL)                     | 4.4 (3.9-4.7)| 4.5 (4.3-4.7)               | 4.5 (4.1-4.7)               | 3.8 (3.4-4.5)               | <.001 |
| Total protein (g/dL)               | 6.9 (6.3-7.2)| 7.0 (6.7-7.3)               | 7.0 (6.4-7.2)               | 6.5 (6.0-7.0)               | <.001 |
| hs-TnI (ng/L)                      | 4.0 (1.9-11.0)| 3.0 (1.8-5.0)              | 3.0 (1.8-8.0)               | 9.0 (2.1-66)                | <.001 |
| Ferritin (µg/L)                    | 0.05 (0.03-0.12)| 0.05 (0.03-0.10)| 0.04 (0.03-0.08)| 0.10 (0.03-0.47) | .003  |
| hs-TnI (ng/L)                      | 12.4 (3.1-73.9)| 9.1 (3.0-35.3)             | 6.9 (1.8-24.4)              | 40.6 (6.8-144)              | <.001 |
| Leucocytes (×10⁹/L)                | 5.65 (4.56-7.59)| 5.32 (4.53-6.36)| 5.51 (4.53-6.70)| 6.63 (4.66-8.97) | .017  |
| Neutrophils (×10⁹/L)               | 3.59 (2.77-5.36)| 3.22 (2.76-4.61)| 3.50 (2.64-4.72)| 4.76 (3.16-7.66) | .001  |
| Lymphocytes (×10⁹/L)               | 1.17 (0.78-1.63)| 1.30 (0.96-1.69)| 1.18 (0.74-1.74)| 0.99 (0.55-1.43) | .001  |
| Platelets (×10⁹/L)                 | 231 ± 85      | 230 ± 79                    | 224 ± 67                    | 239 ± 105                   | .536  |
| Hemoglobin (g/L)                   | 13.8 (12.4-14.7)| 14.6 (13.7-15.5)| 13.6 (12.5-14.6)| 12.8 (11.7-13.8) | <.001 |

**CT-based skeletal muscle measurements**

| Variables                  | All (n = 232) | Tertile 1 (Highest) (n = 78) | Tertile 2 (Middle) (n = 77) | Tertile 3 (Lowest) (n = 77) | P     |
|---------------------------|--------------|-----------------------------|-----------------------------|-----------------------------|-------|
| PMcsa (cm²)               | 32.6 ± 10.2  | 42.8 ± 7.7                  | 31.3 ± 5.3                  | 23.6 ± 6.4                  | <.001 |
| PMcsa index (cm²/m²)      | 11.9 ± 3.7   | 15.6 ± 2.6                  | 11.8 ± 1.6                  | 8.4 ± 2.2                   | <.001 |
| PMma 41.9 (25.3-39.3)     | 33.9 ± 3.7   | 38.4 (33.1-42.2)            | 35.1 (28.0-39.2)            | 28.0 (20.3-33.8)            | <.001 |
| EScsa (cm²)               | 12.1 ± 3.5   | 15.5 ± 2.2                  | 12.1 ± 1.5                  | 8.5 ± 2.3                   | <.001 |
| EScsa index (cm²/m²)      | 41.9 (30.6-47.7)| 45.9 (40.4-49.7)| 42.5 (33.5-47.8)| 31.7 (19.1-42.9) | <.001 |

AST, aspartate amino transaminase; BUN, blood urea nitrogen; CT, computed tomography; ESMcsa, cross-sectional area of the erector spinae muscles; ESMma, muscle attenuation of the erector spinae muscles; hs-TnI, high-sensitive Troponin I, PMma, muscle attenuation of the pectoralis muscles; PMcsa, cross-sectional area of the pectoralis muscles; total SMcsa, cross-sectional area of the total skeletal muscle.

Parameters are mean ± standard deviation or median (interquartile range), n (%). P value less than .05 was considered significant for statistical analyses.
Table 3. CT-Based Skeletal Muscle Measurements and Their Correlation with Other Clinical and Laboratory Variables

| Variables                        | PM\(_{\text{csa}}\) index | PM\(_{\text{ma}}\) | ESM\(_{\text{csa}}\) index | ESM\(_{\text{ma}}\) | Total SM\(_{\text{csa}}\) index |
|----------------------------------|-----------------------------|-----------------|-----------------------------|-----------------|-------------------------------|
|                                  | \(r\)                       | \(P\)           | \(r\)                       | \(P\)           | \(r\)                         | \(P\)       | \(r\)                         | \(P\)       | \(r\)                         | \(P\)       | \(r\)                         | \(P\)       |
| Age                              | -0.44                       | <.001           | -0.50                       | <.001           | -0.39                         | <.001      | -0.70                         | <.001      | -0.46                         | <.001      |
| Duration of hospitalization      | -0.06                       | .334            | -0.14                       | .028            | -0.08                         | .240       | -0.17                         | .010       | -0.09                         | .188       |
| Creatinine                       | 0.04                        | .492            | -0.07                       | .321            | 0.05                          | .417       | -0.14                         | .031       | 0.06                          | .378       |
| AST                              | -0.04                       | .513            | -0.25                       | <.001           | -0.08                         | .191       | -0.35                         | <.001      | -0.06                         | .338       |
| Albumin                          | 0.41                        | <.001           | 0.42                        | <.001           | 0.36                          | <.001      | 0.56                          | <.001      | 0.41                          | <.001      |
| D-dimer                          | -0.34                       | <.001           | -0.33                       | <.001           | -0.32                         | <.001      | -0.42                         | <.001      | -0.36                         | <.001      |
| Ferritin                         | -0.02                       | .720            | -0.08                       | .228            | -0.05                         | .473       | -0.23                         | <.001      | -0.02                         | .739       |
| Procalcitonin                    | -0.21                       | .001            | -0.26                       | <.001           | -0.12                         | .069       | -0.33                         | <.001      | -0.16                         | .012       |
| C-reactive protein               | -0.27                       | <.001           | -0.31                       | <.001           | -0.24                         | <.001      | -0.44                         | <.001      | -0.26                         | <.001      |
| hs-Troponin I                    | -0.29                       | <.001           | -0.36                       | <.001           | -0.24                         | <.001      | -0.45                         | <.001      | -0.28                         | <.001      |
| Neutrophil count                 | -0.20                       | .002            | -0.08                       | .226            | -0.26                         | <.001      | -0.21                         | .001       | -0.24                         | <.001      |
| Lymphocyte count                 | 0.28                        | <.001           | 0.24                        | <.001           | 0.23                          | <.001      | 0.024                         | <.001      | 0.27                          | <.001      |

AST, aspartate amino transaminase; CT, computed tomography; ESM\(_{\text{csa}}\), cross-sectional area of the erector spinae muscles; ESM\(_{\text{ma}}\), muscle attenuation of the erector spinae muscles; hs-TnI, high-sensitive troponin I; PM\(_{\text{ma}}\), muscle attenuation of the pectoralis muscles; PM\(_{\text{csa}}\), cross-sectional area of the pectoralis muscles; total SM\(_{\text{csa}}\), cross-sectional area of the total skeletal muscle.

Table 4. Prediction of In-Hospital Mortality in Patients with COVID-19 by Univariate and Multivariate Cox Proportion Regression Analyses

| Variables                        | Univariate Analysis | Multivariate Analysis |
|----------------------------------|---------------------|-----------------------|
|                                  | Unadjusted HR (95% CI) | \(P\) | Adjusted HR (95% CI) | \(P\) |
| Total SM\(_{\text{csa}}\) index |                      |      |                      |      |
| Age                              | 1.06 (1.03–1.08)     | <.001 | 1.01 (0.98–1.04)     | .427 |
| Gender                           | 1.34 (0.73–2.44)     | .339 | ..                   | ..   |
| Diabetes mellitus                | 3.62 (1.91–6.83)     | <.001 | 2.63 (1.35–5.11)     | .005 |
| Hypertension                     | 4.68 (2.21–9.94)     | <.001 | 2.98 (1.20–7.37)     | .018 |
| hs-Troponin I                    | 1.00 (1.00–1.01)     | .001 | 1.00 (1.00–1.00)     | .151 |
| Coronary artery disease          | 3.28 (1.74–6.17)     | <.001 | 1.36 (0.68–2.72)     | .381 |
| Total SM\(_{\text{csa}}\) index | 0.90 (0.86–0.95)     | <.001 | 0.90 (0.85–0.95)     | <.001 |

CT, computed tomography; HR, hazard ratio; hs-TnI, high-sensitive troponin I; total SM\(_{\text{csa}}\), cross-sectional area of the total skeletal muscle.

Table 5. Optimal Cut-Off Value of Each Computed Tomography-Derived Skeletal Muscle Mass Measurements Predicting for In-Hospital Mortality

| Sensitivity (%) | Specificity (%) | AUC (95% CI) | \(P\) |
|-----------------|-----------------|--------------|------|
| PM\(_{\text{csa}}\) index < 10.3 cm\(^2\)/m\(^2\) | 74 | 76 | 0.81 (0.74–0.88) | <.001 |
| PM\(_{\text{ma}}\) < 33.15 | 60 | 75 | 0.74 (0.67–0.82) | <.001 |
| ESM\(_{\text{csa}}\) index < 11.4 cm\(^2\)/m\(^2\) | 68 | 80 | 0.83 (0.76–0.90) | <.001 |
| ESM\(_{\text{ma}}\) < 37.1 | 73 | 77 | 0.81 (0.74–0.88) | <.001 |
| Total skeletal muscle\(_{\text{csa}}\) index < 21.7 cm\(^2\) | 75 | 80 | 0.85 (0.78–0.91) | <.001 |

AUC, area under the curve; CT, computed tomography; ESM\(_{\text{csa}}\), cross-sectional area of the erector spinae muscles; ESM\(_{\text{ma}}\), muscle attenuation of the erector spinae muscles; PM\(_{\text{ma}}\), muscle attenuation of the pectoralis muscles; PM\(_{\text{csa}}\), cross-sectional area of the pectoralis muscles.
there are conflicting results about the HTN and the severity of COVID-19. Hypertension was not found as an independent factor for COVID-19 severity based on multivariable-adjusted analysis, despite being identified as a risk factor by univariate analysis. Otherwise, several studies showed that HTN may be an independent risk factor for severe COVID-19. In our study, we found an independent relationship between HTN and mortality of COVID-19.

Short periods of reduced activity have been found to result in rapid loss of muscle mass and physical function, even in younger adults. Due to the COVID-19 measures, the sudden decrease in activities and the increase in sedentarism may closely reflect the "catabolic crisis" model of sarcopenia, according to the study conducted by English and Paddon-Jones.

Inflammation has been shown to increase catabolic pathways and inhibit anabolic pathways, thus reducing net muscle protein synthesis. Tumor necrosis factor (TNF)-α, the key transcription factor in SM atrophy, downregulates the myogenesis and upregulates nuclear factor–kappa beta. In some patients with cytokine storm observed during the current COVID-19 outbreak, it becomes more pronounced with increased levels of pro-inflammatory cytokines such as interferon, IL-6, IL-12. Also, increment of TNF-α, CRP, and MCP1 has been observed in severe COVID-19 patients. These cytokines not only directly contribute to tissue damage but can also contribute to sarcopenia by blunting muscle protein synthesis (MPS) during and after immobilization.

Ufuk et al. found a significant association of pneumonia severity, PMcsa index, and PMcsa with length of stay, IMV, and mortality among COVID-19 patients who underwent CT at admission. In light of this information, we found DM, HTN, and total SMcsa index on chest CT in patients with COVID-19 are the independent predictors of the mortality.

In our study, the relationship between skeletal groups [ESM, PM, and total SM] and mortality in this patient group was assessed. Therefore, unlike similar studies, not a single muscle group but 3 different muscle groups were evaluated. Moreover, in our study, muscle attenuation was assessed in addition to other studies, and it was shown to be a predictor of in-hospital mortality. The patient population was larger than similar studies. Due to the high number of patients, the mortality data of our study were more powerful. In addition to cardiovascular risk factors, cardiac drug groups and percentages of use were shown. It was shown that cardiovascular risk factors and cardiac medical treatment intensity are high in the sarcopenic group.

Limitations
This study had some limitations. Primarily, the study has been retrospectively conducted in a single tertiary hospital, and the sample size was not large enough. As a result, PMcsa index, ESMcsa index, and total SMcsa index are significantly associated with mortality in COVID-19 patients. These parameters can be easily evaluated in chest CT images of COVID-19 patients, and we propose that these parameters might be beneficial in routine clinical practice because these parameters with prognostic value are obtained without additional examination.
Conclusion
This study has shown that sarcopenia is a predictor of survival in COVID–19 patients with cardiovascular risk factors.

Data Availability Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics Committee Approval: Ethics committee approval was received from the Ankara City Hospital Ethics Commission No. 1 (Approval Date: May 21, 2020; Approval Number: E1-20-505).

Informed Consent: Written informed consent was waived by the Ethics Commission.

Peer-review: Externally peer-reviewed.

Author Contributions: Concept – K.G.Y.; Design – M.A.E., A.K.K., K.G.Y., A.K.E.; Supervision – F.C.E., A.G.E.; Materials – Ç.Y.; Data Collection and/or Analysis – B.K., İ.H., F.C.E., M.S.B., A.K.K.; Analysis and/or Interpretation – M.E., M.S.B.; Literature Review – A.G.E.; Writing – Ç.Y., A.K.E.; Critical Review – M.A.E., H.R.G.

Declaration of Interests: None.

Funding: The authors received no financial support for the research.

References
1. Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733. [CrossRef]
2. World Health Organization. Coronavirus (COVID–19) Dashboard; 2021. Available at: https://covid19.who.int/region/euro/country/t rat; https://covid19.who.int/region/euro/country/tr.
3. Ohana M, Muller J, Severac F, et al. Temporal variations in the diagnostic performance of chest CT for Covid–19 depending on disease prevalence: experience from North–Eastern France. Eur J Radiol. 2021;134:109425. [CrossRef]
4. Cruz–Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48:16–31.
5. Atkins JI, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannameetee SG. Sarcopenic obesity and risk of cardiovascular disease and mortality: a population–based cohort study of older men. J Am Geriatr Soc. 2014;62(2):253–260. [CrossRef]
6. Beretta MV, Dantas Filho FF, Freiberg RE, Feldman JV, Nery C, Rodrigues TC. Sarcopenia and type 2 diabetes mellitus as predictors of 2-year mortality after hospital discharge in a cohort of hospitalized older adults. Diabetes Res Clin Pract. 2020;159:107969. [CrossRef]
7. Attaway AH, Welch N, Hatipoğlu U, Zein JG, Dasarathy S. Muscle loss contributes to higher morbidity and mortality in COPD: an analysis of national trends. Respiriology. 2021;26(1):62–71. [CrossRef]
8. Nakano A, Ohkubo H, Taniguchi H, et al. Early decrease in erector spinae muscle area and future risk of mortality in idiopathic pulmonary fibrosis. Sci Rep. 2020;10(1):2312. [CrossRef]
9. Nishimura JM, Ansari AZ, D’Souza DM, Moffatt–Bruce SD, Merritt RE, Kneuerz PJ. Computed tomography–assessed skeletal muscle mass as a predictor of outcomes in lung cancer surgery. Ann Thorac Surg. 2019;108(5):1555–1564. [CrossRef]
10. Rutten JG, Ubachs J, Kruitwagen RFPM, Beets–Tan RHG, Olde Damink SWM, Van Gorp T. Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer. J Cachexia Sarcopenia Muscle. 2017;8(4):630–638. [CrossRef]
11. Moon SW, Choi JS, Lee SH, et al. Thoracic skeletal muscle quantification: low muscle mass is related with worse prognosis in idiopathic pulmonary fibrosis patients. Respir Res. 2019;20(1):35. [CrossRef]
12. Awano N, Inomata M, Kuse N, et al. Quantitative computed tomography measures of skeletal muscle mass in patients with idiopathic pulmonary fibrosis according to a multidisciplinary discussion diagnosis: a retrospective nationwide study in Japan. Respir Investig. 2020;58(2):91–101. [CrossRef]
13. Oh J, Shin WJ, Jeong D, et al. Low muscle mass as a prognostic factor for early postoperative outcomes in pediatric patients undergoing the Fontan operation: a retrospective cohort study. J Clin Med. 2019;8(8):1257–1268. [CrossRef]
14. Cruz–Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(4):601. [CrossRef]
15. Teigen LM, John R, Kuchnia AJ, et al. Preoperative pectoralis muscle quantity and attenuation by computed tomography are novel and powerful predictors of mortality after left ventricular assist device implantation. Circ Heart Fail. 2017;10(9):e004069. [CrossRef]
16. Kinsey CM, San Jose Estepar R, van der Velden J, Cole BF, Christiansen DC, Washko GR. Lower pectoralis muscle area is associated with a worse overall survival in non–small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 2017;26:38–43.
17. Ufuk F, Demirci M, Sagtas E, Akbudak IH, Ugurlu E, Sari T. The prognostic value of pneumonia severity score and pectoralis muscle area on chest CT in adult COVID–19 patients. Eur J Radiol. 2020;131:109271. [CrossRef]
18. Kirwan R, McCullough D, Butler T, Perez de Heredia F, Davies IG, Stewart C. Sarcopenia during COVID–19 lockdown restrictions: long–term health effects of short–term muscle loss. GeroScience. 2020;42(6):1547–1578. [CrossRef]
19. Du RH, Liang LR, Yang CQ, et al. Predictors of mortality for patients with COVID–19 pneumonia caused by SARS–CoV–2: a prospective cohort study. Eur Respir J. 2020;55(5):2000524–2000532. [CrossRef]
20. Pettili CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966. [CrossRef]
21. Zhou F, Yu T, D u R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID–19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. [CrossRef]
22. Kumar A, Arora A, Sharma P, et al. Is diabetes mellitus associated with mortality and severity of COVID–19? A meta–analysis. Diabetes Metab Syndr. 2020;14(4):535–545. [CrossRef]
23. Shibata S, Arima H, Asayama K, et al. Hypertension and related diseases in the era of COVID–19: a report from the Japanese Society of Hypertension Task Force on COVID–19. Hypertens Res. 2020;43(10):1028–1046. [CrossRef]
24. Cal Q, Chen F, Wang T, et al. Obesity and COVID–19 severity in a designated hospital in Shenzhen, China. Diabetes Care. 2020;43(7):1392–1398. [CrossRef]
25. Shi Y, Yu X, Zhao H, Wang R, Zhao R, Sheng J, host. Host susceptibility to severe COVID–19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24(1):108. [CrossRef]
26. Breen L, Stokes KA, Churchward–Venne TA, et al. Two weeks of reduced activity decreases leg lean mass and induces “anabolic resistance” of myofibrillar protein synthesis in healthy elderly. J Clin Endocrinol Metab. 2013;98(6):2604–2612. [CrossRef]
27. English KL, Paddon–Jones D. Protecting muscle mass and function during illness and hospitalization. J Cachexia Sarcopenia Muscle. 2020;11(3):323–334. [CrossRef]
28. Lilliu Y, Timmis R, Perneger TV, et al. Overweight and obesity in patients with COVID–19, a potentially preventable risk of hospitalization and death. Front Public Health. 2020;8:320. [CrossRef]
29. Breen L, Stokes KA, Churchward–Venne TA, et al. Two weeks of reduced activity decreases leg lean mass and induces “anabolic resistance” of myofibrillar protein synthesis in healthy elderly. J Clin Endocrinol Metab. 2013;98(6):2604–2612. [CrossRef]
30. English KL, Paddon–Jones D. Protecting muscle mass and function during illness and hospitalization. J Cachexia Sarcopenia Muscle. 2020;11(3):323–334. [CrossRef]